Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.55 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.52 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 6/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30480288 | 0.90 | MKNK1 (0.49) | MKNK1MKNK2TLR9TLR8TLR7 | |
| SCHEMBL3178410 | 0.87 | NOS3 (0.45) | MKNK1MKNK2TLR9TLR8TLR7 | |
| SCHEMBL29940481 | 0.87 | NOS3 (0.45) | MKNK1MKNK2TLR9TLR8TLR7 | |
| SCHEMBL22272915 | 0.83 | BACE1 (0.49) | MKNK1MKNK2TLR9TLR8TLR7 | |
| SCHEMBL24692545 | 0.81 | BACE1 (0.51) | MKNK1MKNK2TLR9TLR8TLR7 | |
| SCHEMBL30279702 | 0.81 | BACE1 (0.51) | MKNK1MKNK2TLR9TLR8TLR7 | |
| SCHEMBL19723895 | 0.81 | BACE1 (0.51) | MKNK1MKNK2TLR9TLR8TLR7 | |
| Bromide SCHEMBL28072385 | 0.80 | BACE1 (0.50) | MKNK1MKNK2TLR9TLR8TLR7 | |
| SCHEMBL5584524 | 0.79 | TLR7 (0.56) | TLR9TLR8TLR7QDPRHTR2C | |
| SCHEMBL31510721 | 0.79 | QDPR (0.56) | TLR9TLR8TLR7QDPRHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852584-B1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| EP-2852584-B1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2018-02-28 | — | — | EP | disclosed |
| US-9399636-B2 | Substituted dipyridylamines and uses thereof | GENENTECH, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399636-B2 | Substituted dipyridylamines and uses thereof | GENENTECH, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2852584-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| US-20150080367-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080367-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| CN-104271566-A | Substituted dipyridylamines and uses thereof | HOFFMANN LA ROCHE | 2015-01-07 | — | — | CN | disclosed |
| WO-2013174780-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013174780-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080367-A1 | SUBSTITUTED DIPYRIDYLAMINES AND USES THEREOF | PDXK, PRMT1, DMPK | MKNK1 121/4885MKNK2 124/4885TLR9 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.